AcelRx Pharmaceuticals(ACRX) - 2024 Q1 - Quarterly Report

Financial Performance - Total current assets increased to $19,953,000 as of March 31, 2024, compared to$11,576,000 as of December 31, 2023, representing a 72% increase[21]. - The net loss for Q1 2024 was $3,954,000, a decrease from a net loss of$8,152,000 in Q1 2023, reflecting a 51% improvement[24]. - Cash and cash equivalents rose to $12,122,000 at the end of Q1 2024, compared to$5,721,000 at the beginning of the period, marking a 112% increase[31]. - Total liabilities increased to $12,438,000 as of March 31, 2024, from$6,290,000 as of December 31, 2023, representing a 98% increase[21]. - The company’s accumulated deficit reached $448,180,000 as of March 31, 2024, compared to$444,226,000 at the end of 2023[21]. - The Company recorded approximately $6.1 million as a liability from the sale of future payments related to DSUVIA, with$1.2 million recognized as other income[52]. - Total other income (expense), net for Q1 2024 was $283,000, a decrease of 95$5.4 million in Q1 2023[132]. - Interest income and other income, net for Q1 2024 was $220,000, up 10$200,000 in Q1 2023[133]. - Cash used in operating activities for Q1 2024 was $2.9 million, reflecting a net loss of$4.0 million[146]. - Cash provided by financing activities for Q1 2024 was $12.0 million, primarily due to net proceeds from the XOMA Purchase Agreement and the January 2024 private placement[150]. Research and Development - Research and development expenses for Q1 2024 were$1,433,000, up from $1,047,000 in Q1 2023, indicating a 37$6.0 million in gross proceeds from a private placement on January 22, 2024, with additional potential proceeds of $10.0 million and$2.0 million contingent on clinical trial results and stock price performance, respectively[79][80][81]. - The first tranche of the January 2024 private placement resulted in gross proceeds of approximately $6.0 million, with pre-funded warrants issued for up to 7,792,208 shares[139]. - The second tranche of the January 2024 private placement could provide additional gross proceeds of approximately$10.0 million, contingent on achieving specific clinical trial endpoints[140]. - The company expects to incur significant losses in 2024 and may require additional capital to fund operations within the next twelve months[136]. - The company has financed its operations primarily through equity securities issuance, borrowings, and payments from partners, including a recent agreement to monetize future payments related to DSUVIA sales[167]. Acquisitions and Agreements - On April 3, 2023, the Company completed the DSUVIA Agreement with Alora Pharmaceuticals, acquiring certain assets related to the sufentanil sublingual tablet product[39]. - The Company acquired Lowell Therapeutics, Inc. on January 7, 2022, gaining the Niyad™ product, which has received Breakthrough Device Designation from the FDA[40]. - Talphera entered into a Payment Interest Purchase Agreement with XOMA for $8 million related to certain receivables from the DSUVIA Agreement[38]. - The Company entered into an Asset Purchase Agreement with Alora for the acquisition of assets related to DSUVIA, with a total consideration of$1.1 million and potential sales-based milestones of up to $116.5 million[65]. - In January 2024, the Company sold certain receivables to XOMA for$8.0 million, with proceeds from the sale of future payments amounting to $6.133 million as of March 31, 2024[67]. Operational Challenges - The company has incurred recurring operating losses and negative cash flows since inception, raising substantial doubt about its ability to continue as a going concern[42]. - The company has ongoing litigation risks that may materially adversely affect its financial condition and results of operations[78]. - The company has identified risks related to potential delays in clinical trials and regulatory approvals, which could increase costs and jeopardize product development[163]. - The company may experience significant disruptions in financial markets, impacting its ability to obtain additional capital on favorable terms[174]. - The company may face difficulties in raising additional capital, which could force it to scale back or discontinue product development and commercialization efforts[173]. - The company has a material weakness in its internal control over financial reporting, which may result in errors in financial statements[164]. - Global supply chain disruptions may adversely impact the company's ability to develop and supply its product candidates[115]. Future Outlook - The company expects significant additional capital will be needed in the future to continue planned operations and capital requirements[176]. - The company may need to relinquish or license its rights to technologies or products under unfavorable terms if it cannot secure sufficient funding[173]. - The ability to generate future revenues from product sales depends heavily on successful clinical trials and regulatory approvals[188]. - The approval process for PMA or NDA is lengthy and may incur unexpected delays and costs, impacting the company's financial condition[203]. - The FDA's rejection of clinical data could adversely affect the company's ability to obtain marketing authorization for its product candidates[204]. - The company may need to conduct additional clinical development work to obtain FDA approval, which would increase expenses and delay revenue[205]. - The company may face unexpected liabilities from the acquisition of Lowell, which could adversely affect its financial condition[184].